Vorolanib Tablets
Sponsors
Hao Zeng, Dong Wen
Conditions
AdjuvantImmunotherapyMolecular Targeted TherapyRenal Cell CarcinomaRenal Cell Carcinoma (RCC)
Phase 2
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
Not yet recruitingNCT06523049
Start: 2024-08-31End: 2026-09-30Target: 67Updated: 2024-07-26
Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma
Active, not recruitingNCT07047001
Start: 2025-04-24End: 2032-06-30Target: 60Updated: 2025-07-09